PTOWSBI43 (67-09)
`Approved far use thro sgh O7FSi2012. OMB 0864-0051
`a
`LES, Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`
`ofinfos
`idnder the Papenvark Recuction Act of 1905, no parzons are requiredto raupend to 2 collection
`
`DISCLAIMER IN PATENT UNDER 37 CFR 4.3213}
`
`i Nameof Paientes
`Apotex Technologies, Inc.
`Patent Number
`7,049,328
`Iie of Inventiar
`
`USE FOR DEFERIPRONE
`
`i Dackel Numoer (Ostionah
`
`Date Patent bsued
`May23, 2006
`
`i hereby disclaim the following complete claims in the above identified patent:ota
`
`The extent of my interest in said patent is (if assignee of record, state fiher and sage, or reel and frame, where
`| assignmentisrecorded):
`100% (Assignment Recorded at Reel 638613, Frame 6922
`
`| The fae for this disclaimeris sat forth in 37 CFR 1.20(9}.
`: P| Pateniae claims small entity aiatus. See 37 CFR 1.27.
`P| Simail entity status has already bean established in this case, and is still proper.
`UW A checkin the arnount ofthe izeis anciosed,
`a The Ctrectoris hereby authorized te charge any fees which may be required orcracit any
`
`Payment by credit card. Form PYO-2038 is atlached.
`
`overpayment to Deposit Account No.
`
`WARNING: Information on this form may become public. Credit card information should nat
`be included on this form. Provide credit card information and authorization on PTO-2038,
`
`Prone,
`State of
`
`,
`
`r
`SS
`Pads
`PEE
`
`ahs
`
`my
`Caines SUE«
`
`City, State, Zip Code or Foreign Country as applicable
`
`ona,ts&
`Signed ato
`
`4
`SFSim!
`Ps
`setieegniny
`2Be
`ape
`caangncnnnneseshoes—Jawwagid
`
`Signature
`.
`Robert Shapiro, Global Director, Portfolio Management
`
`Typed or printed name of patentee/ attamey or agent of record
`Apotex Technologies, Inc. 150 Signet Drive
`Addres:
`meee
`
`Taronto, Canada MSL iTS
`
`Registration Number,if
`apolicable
`1 416-749-9300
`Telephone Number
`
`This collection of information is required by 37 CPR 1.324. The information is required to obiein o retain a henefil by the public which is fe fle (and by the
`
`USPTO te process) an application, Confidentiality is governad by 38 L.3.C. 122 and 37 CFR 1.41 and 1.14, This collectionisestimated to take 12 minutes to
`
`complete, Including gathering, preparing, and submitting ihe compieted application form to the USPTO. Time will vary de
`fing upon the individual case.
`
`
`
`Any comments on the arrnount of ime you require io compete
`i andlor suggestions for raducing this burden, shouid be sent te the Chief inferrnation
`
`
`Officer, US. Paient anc Trademark Gifice, LOS. Department of Commerce, P.O).Box 1450, Alexandria, VA 22513-4460. DO MOT SEND FEES OR
`
`COMPLETED FORMS TO THIS ADORESS, SENG TO: Commissioner far Patents, P.O. Bax 1480, Aloxandria, VA 22373-4489,
`
`if you need asgistance in completing the farm, call 1-200-P70.9799 and select option 2.
`
`Apotex Tech.
`Ex. 2017
`
`Apotex Tech.
`Ex. 2017
`
`

`

`Electronic Patent Application Fee Transmittal
`
`Title of Invention:
`
`USE FOR DEFERIPRONE
`
`eine
`
`Extension-of-Time:
`
`Filing Fees for U.S. National Stage under 35 USC 371
`
`Description
`
`Fee Code
`
`Quantity
`
`Sub-Total in
`
`USD(S)
`
`Basic Filing:
`
`Miscellaneous-Filing:
`
`Patent-Appeals-and-Interference:
`
`Post-Allowance-and-Post-Issuance:
`
`

`

`Description
`
`Miscellaneous:
`
`Total in USD ($)
`
`Sub-Total in
`USD(S)
`
`Fee Code
`
`Quantity
`
`

`

`International Application Number:
`
`Confirmation Number:
`
`2281
`
`Title of Invention:
`
`USE FOR DEFERIPRONE
`
`Electronic AcknowledgementReceipt
`
`Application Number:
`
`10311814
`
`
`
`a
`
`Paymentinformation:
`
`The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpaymentas follows:
`
`
`
`[Pevostacone——SSSCSCSC~*sdSCS
`
`

`

`File Listing:
`
`Pages
`Multi
`File Size(Bytes)/
`DocumentDescription
`Document
`
`
`
`Number Message Digest|Part/.zip|P (if appl.)
`
`1
`
`Statutory disclaimers per MPEP 1490
`
`Executed-1-321.pdf
`
`€24d83 10f9230c6c4292e563f94bc165a099}
`b291
`
`1
`
`Information:
`
`The page size in the PDF is too large. The pages should be 8.5 x 11 or A4.If this PDF is submitted, the pageswill be resized upon entry into the
`Image File Wrapper and mayaffect subsequent processing
`
`Information:
`
`3
`
`Assignee showing of ownership per 37
`CFR 3.73
`
`Executed-3-73bpdf
`
`a13420d5c7da61381b7285544a68eb048ay
`36763
`
`1
`
`The page size in the PDF is too large. The pages should be 8.5 x 11 or A4.If this PDF is submitted, the pageswill be resized upon entry into the
`Image File Wrapper and mayaffect subsequent processing
`
`Information:
`
`3
`
`Fee Worksheet (SB06)
`
`fee-info.pdf
`
`95203d0dd4b6920e72400106b27e0d7340|
`059cef
`
`2
`
`

`

`This AcknowledgementReceipt evidences receipt on the noted date by the USPTO ofthe indicated documents,
`characterized by the applicant, and including page counts, where applicable.It serves as evidence of receipt similar to a
`Post Card, as described in MPEP 503.
`
`the application.
`
`New Applications Under 35 U.S.C. 111
`If a new application is being filed and the application includes the necessary componentsfora filing date (see 37 CFR
`1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shownonthis
`AcknowledgementReceiptwill establish the filing date of the application.
`National Stage of an International Application under 35 U.S.C. 371
`If a timely submission to enter the national stage of an international application is compliant with the conditions of 35
`U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903indicating acceptanceof the application as a
`national stage submission under35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.
`New International Application Filed with the USPTO as a Receiving Office
`If a new international application is being filed and the international application includes the necessary components for
`an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number
`and of the International Filing Date (Form PCT/RO/105)will be issued in due course, subject to prescriptions concerning
`national security, and the date shownon this AcknowledgementReceiptwill establish the international filing date of
`
`